Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where J.M. Moreno Planas is active.

Publication


Featured researches published by J.M. Moreno Planas.


Transplantation Proceedings | 2003

Late mortality in patients with liver transplantation: causes and risk factors

J.M. Moreno Planas; E. Rubio González; A Herreros De Tejada; F. Pons Renedo; V. Sánchez-Turrión; B. Velayos Jiménez; A. Gómez Cruz; Javier López-Monclús; V. Cuervas-Mons Martı́nez

LIVER TRANSPLANTATION (OLT) has become the treatment of choice for end-stage liver failure. Survival after OLT has improved over recent years owing to improved surgical and medical management of these patients. The majority of deaths occur during the first 3 months after liver transplantation, mainly due to infections, allograft failure following primary allograft dysfunction and nonfunction, and technical causes. Although causes of early mortality are well defined, there is a paucity of data on causes of death in long-term survivors of liver transplantation. The aim of this study was to review the causes of late mortality (more than 1 year after OLT) in liver transplant patients in a single adult Liver Transplantation Center.


Journal of Hepatology | 2003

Effectiveness and security of mycophenolate mofetil as monotherapy in liver transplantation

J.M. Moreno Planas; E Rubio; Javier López-Monclús; A. Gomez; A. Herreros; Juan de la Revilla; E Navarrete; V. Sanchez; V. Cuervas-Mons

INTRODUCTION Calcineurin inhibitors (CIs) cause substantial long-term morbidity and mortality among orthotopic liver transplantation (OLT) patients. Our aim was to evaluate the effectiveness and safety of mycophenolate mofetil (MMF) among OLT patients with CI-related side effects. PATIENTS Thirty three adult patients, including 29 men and 4 women of mean age 57 years, underwent OLT between 1986 and 2000 under treatment with CIs (28 cyclosporine and five tacrolimus). Mean follow-up after OLT was 59 months. Adverse effects were renal dysfunction in 26, hypertension in 23, and neurotoxicity in two. MMF was added gradually while simultaneously reducing the dosage of CI. RESULTS After a mean 15-months follow-up of MMF treatment, CIs had been withdrawn in 28 patients (85%). The mean time from the initiation of MMF and CI withdrawal was 5 months. During the first year of follow-up chronic renal dysfunction improved in 16 of 26 patients (61.6%) accompanied by a decreased serum creatinine and urea and an increase in creatinine clearance. Among 13/23 (56.5%) hypertensive patients, there was a significant decrease in blood pressure or the number of antihypertensive drugs (P<.05). One patient with neurotoxicity improved. Twenty-two patients (66%) displayed adverse events: five rejections (15%) including four acute episodes, controlled by CI re-introduction, and one chronic reaction. The most frequent adverse effects were herpes simplex infection in 10 patients (30%), asthenia in nine (27%), diarrhea in five (15%) and thrombocytopenia in four (12%). Nevertheless, only six patients (19%) required MMF dose reduction, namely, three patients with GI intolerance, two with repeated VHS infections, and one with anemia. CONCLUSIONS MMF monotherapy improves renal function and blood pressure levels in more than 50% of patients with chronic renal impairment and hypertension after OLT. Many of the side effects of MMF were mild; it was safe accompanied by a low incidence of rejection reactions.


Transplantation Proceedings | 2005

Peginterferon and ribavirin in patients with HCV cirrhosis after liver transplantation.

J.M. Moreno Planas; E. Rubio González; E. Boullosa Graña; A. Garrido Botella; C. Barrios Peinado; J.L. Lucena de la Poza; M. Jiménez Garrido; V. Sánchez Turrión; V. Cuervas-Mons Martı́nez


Transplantation Proceedings | 2005

Adefovir Dipivoxil Therapy in Liver Transplant Recipients With Lamivudine-Resistant Hepatitis B Virus

A. Herreros de Tejada Echanojáuregui; J.M. Moreno Planas; E. Rubio González; F. Portero Azorin; J. López Monclús; J. Revilla Negro; J.L. Lucena de la Poza; V. Sánchez Turrión; C. Barrios Peinado; V. Cuervas-Mons Martı́nez


Congress of the Andalusian Society of Organ and Tissue Transplantation | 2005

Therapy of Intractable Pruritus With MARS

M. Acevedo Ribó; J.M. Moreno Planas; C. Sanz Moreno; E. Rubio González; E. Boullosa Graña; V. Sánchez-Turrión; D. Sanz Guajardo; V. Cuervas-Mons


Transplantation Proceedings | 2005

Effectiveness of pegylated interferon and ribavirin in patients with liver HCV cirrhosis.

J.M. Moreno Planas; E. Rubio González; E. Boullosa Graña; M. Fernández Ruiz; M. Jiménez Garrido; J.L. Lucena de la Poza; F. Martı́nez Arrieta; C. Molina Miliani; V. Sánchez Turrión; V. Cuervas-Mons Martı́nez


Transplantation Proceedings | 2005

Prevalence of Hepatitis C Virus Genotypes in a Spanish Liver Transplant Unit

J.M. Moreno Planas; M. Fernández Ruiz; F. Portero Azorin; E. Boullosa Graña; E. Rubio González; S. Martı́n Garcia; F. Martı́nez Arrieta; M. Jiménez Garrido; V. Sánchez Turrión; V. Cuervas-Mons Martı́nez


Transplantation Proceedings | 2005

Efficacy of Hepatocellular Carcinoma Locoregional Therapies on Patients Waiting for Liver Transplantation

J.M. Moreno Planas; J. López Monclús; A. Gómez Cruz; E. Rubio González; R. Pérez Arangüena; E. Boullosa Graña; A. Garcia Suarez; J.L. Pérez-Picouto; M. Fernández Ruiz; J.L. Lucena de la Poza; V. Sánchez Turrión; V. Cuervas-Mons Martı́nez


Transplantation Proceedings | 2005

Results of liver transplantation in patients with previous portosystemic shunts.

E. Rubio González; J.M. Moreno Planas; M. Jiménez Garrido; J.L. Lucena de la Poza; F. Martı́nez Arrieta; V. Cuervas-Mons; V. Sánchez Turrión


Revista español de enfermedades digestivas | 2002

Enfermedad de Wilson y embarazo

J.M. Moreno Planas; L. Broseta Viana; C. Herrero Quiros; J.M. Calbo Mayo; M. Garcia Rayo; R. Pérez Flores

Collaboration


Dive into the J.M. Moreno Planas's collaboration.

Top Co-Authors

Avatar

E. Rubio González

Autonomous University of Madrid

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

A. Gómez Cruz

Autonomous University of Madrid

View shared research outputs
Top Co-Authors

Avatar

F. Pons Renedo

Autonomous University of Madrid

View shared research outputs
Top Co-Authors

Avatar

Javier López-Monclús

Autonomous University of Madrid

View shared research outputs
Top Co-Authors

Avatar

V. Cuervas-Mons

Autonomous University of Madrid

View shared research outputs
Top Co-Authors

Avatar

A Herreros De Tejada

Autonomous University of Madrid

View shared research outputs
Top Co-Authors

Avatar

B. Velayos Jiménez

Autonomous University of Madrid

View shared research outputs
Top Co-Authors

Avatar

D. Sanz Guajardo

Autonomous University of Madrid

View shared research outputs
Top Co-Authors

Avatar

E Navarrete

Autonomous University of Madrid

View shared research outputs
Researchain Logo
Decentralizing Knowledge